Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: A phase I/II trial

Leukemia and Lymphoma

Volumn 45, Issue 4, 2004, Pages 749-754

  Koskela, Kari ^a,b   Pelliniemi, Tarja Terttu ^a   Pulkki, Kari ^a,b   Remes, Karis ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

ATRA; Chemosensitivity; Chemotherapy; Cytokine; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; PARAPROTEIN; PREDNISONE; RETINOIC ACID; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TOLERABILITY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; INFECTION; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MULTIPLE MYELOMA; MYELOMA CELL; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; TUMOR GROWTH; XEROSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CELL DIVISION; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ONCOSTATIN M; PEPTIDES; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME; TRETINOIN;

EID: 1342266120     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001628158     Document Type: Article

References (29)

1. Ogata, A., Nishimoto, N., Shima, Y., Yoshizaki, K. and Kishimoto, T. (1994) "Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction", Blood, 84, 3040-3046.
2. Palumbo, A., Battaglio, S., Napoli, P., Bruno, B., Omedé, P., Boccadoro, M., et al. (1995) "Retinoic acid inhibits the growth of human myeloma cells in vitro", British Journal of Haematology, 89, 555-560.
3. Pulkki, K., Neva, M., Koskela, K., Ollikainen, H., Remes, K. and Pelliniemi, T.-T. (1995) "IL-6-receptor-mediated growth inhibition by all-trans retinoic acid but not by interferon-α in human myeloma cells", Annals of New York Academy of Sciences, 762, 457-458.
4. Sidell, N., Taga, T., Hirano, T., Kishimoto, T. and Saxon, A. (1991) "Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors", The Journal of Immunology, 146, 3809-3814.
5. Smith, M.R., Xie, T., Joshi, I. and Schilder, R.J. (1998) "Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells", British Journal of Haematology, 102, 1090-1097.
6. Chen, Y., Desai, P., Shiao, R., Lavelle, D., Haleem, A. and Chen, J. (1996) "Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid:synergy through modulation of interleukin-6 autocrine loop at multiple sites", Blood, 87, 314-323.
7. Tosi, P., Pellacani, A., Visani, G., Ottaviani, E., Ronconi, S., Zamagni, E., et al. (1999) "In vitro treatment with retinoids decreases bc-2 protein expression and enhances dexamethasone-induced cytotocity and apoptosis in multiple myeloma cells", European Journal of Haematology, 62, 143-148.
8. Vesole, D., Kornbluth, J., Jagannath, S., Sznol, M., Mattox, S., Vaught, L., et al. (1993) "Biological response modifiers in refractory multiple myeloma: lack of clinical efficacy of recombinant human interieukin-4 and all-trans retinoic acid", Blood, 82(suppl. 1), 263a.
9. Niesvizky, R., Siegel, D.S., Busquets, X., Nichols, G., Muindi, J., Warrell, R.P.J., et al. (1995) "Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma", British Journal of Haematology, 89, 217-218.
10. Musto, P., Falcone, A., Sajeva, M.R., D'Arena, G., Bonini, A. and Carotenuto, M. (1995) "All-trans retinoic acid for advanced multiple myeloma", Blood, 85, 3769-3770.
11. Hussein, M.A., Bocock, K., Bloom, T., Finke, J., Rybicki, L., Scott, R., et al. (1998) "Biologic and clinical evaluation of high intermittent dose all trans retinoic acid (ATRA) in refractory multiple myeloma patients", Blood, 92, 108a
12. Durie, B.G.M. and Salmon, S.E. (1975) "A clinical staging system for multiple myeloma", Cancer, 36, 842-854.
13. Adamson, P.C., Boylan, J.F., Balis, F.M., Murphy, R.F., Godwin, K.A., Gudas, L.J., et al. (1993) "Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein", Cancer Research, 53, 472-476.
14. Lefebvre, P., Thomas, G., Gourmel, B., Agadir, A., Castaigne, S., Dreux, C., et al. (1991) "Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia", Leukemia, 5, 1054-1058.
15. Klein, B., Zhang, X., Lu, Z. and Bataille, R. (1995) "Interleukin-6 in human multiple myeloma", Blood, 85, 863-872.
16. Zhang, X., Klein, B. and Bataille, R. (1989) "Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma", Blood, 74, 11-13.
17. Labaume, S., Chopin, M., Pla, M. and Brouet, J.C. (1998) "Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells", Leukemia and Lymphoma, 30, 361-366.
18. Okamura, T., Masuda, M., Arai, Y., Ishida, C., Shudou, K. and Mizoguchi, H. (1998) "All-trans retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combination with anti-Fas monoclonal antibody in the human myeloma cell line, U266B1", Experimental Hematology, 26, 501-506.
19. Joseph, B., Lefebvre, O., Méreau-Richard, C., Danzé, P., Belin-Plancot, M. and Formstecher, P. (1998) "Evidence for the involvement of both retinoic acid receptor- and retinoic X receptor-dependent signaling pathways in the induction of tissue transglutaminase and apoptosis in the human myeloma cell line RPMI 8226", Blood, 91, 2423-2432.
20. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", The New England Journal of Medicine, 341, 1565-1571.
21. Raje, N. and Anderson, K.C. (1999) "Thalidomide-A revival story", The New England Journal of Medicine, 341, 1606-1609.
22. Oikawa, T., Hirotani, K., Nakamura, O., Shudo, K., Hiragun, A. and Iwaguchi, T. (1989) "A highly potent antiangiogenic activity of retinoids", Cancer Letters, 48, 157-162.
23. Weber, D.M., Bseiso, A., Wood, A., Gavino, M. and Alexanian, R. (1997) "All-trans retinoic acid for multiple myeloma", Blood, 90(suppl. 1), 357a.
24. Musto, P., Sajeva, M.R., Sanpaolo, G., D'Arena, G., Scalzulli, P.R. and Carotenuto, M. (1997) "All-trans retinoic acid in combination with α-interferon and dexamethasone for advanced multiple myeloma", Haematologica, 82, 354-356.
25. Bataille, R., Chappard, D. and Klein, B. (1992) "Mechanisms of bone lesions in multiple myeloma", Hematology/Oncology Clinics of North America, 6, 285-295.
26. Koskela, K., Pelliniemi, T-T., Remes, K., Rajamäki, A. and Pulkki, K. (1997) "Serum oncostatin M in multiple myeloma: association with prognostic factors", British Journal of Haematology, 96, 158-160.
27. Wierzbowska, A., Urbanska-Rys, H. and Robak, T. (1999) "Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma", British Journal of Haematology, 105, 412-419.
28. Koskela, K., Pelliniemi, T.-T., Rajamäki, A., Pulkki, K. and Remes, K. (2000) "Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis", European Journal of Haematology, 65, 52-56.
29. Adamson, P.C. (1994) "Pharmacokinetics of all-trans retinoic acid: clinical implications in acute promyelocytic leukemia", Seminars in Hematology, 31, 14-17.